article thumbnail

Construction starts on $400m biosimilars production centre in Slovenia

European Pharmaceutical Review

Once completed, the 40,000-square-metre centre will be used to produce active pharmaceutical ingredients (API) for biosimilars in Sandoz’s rheumatology, oncology and immunology portfolio. Sandoz is the parent company of Lek Pharmaceuticals , the oldest pharmaceutical company in Slovenia.